5d
Zacks Small Cap Research on MSNIMNN: Phase 3 Ovarian Cancer Trial to get Underway in Mar 2025…IMNN READ THE FULL IMNN RESEARCH REPORT Business Update Phase 3 Ovarian Cancer Trial to Initiate in March 2025 Imunon, Inc. (NASDAQ:IMNN) is continuing preparations to conduct a Phase 3 clinical trial ...
Anova Enterprises, Inc. (Anova), a technology-enabled CRO dedicated to accelerating promising treatments, has announced enrollment of the first two pa ...
Early-phase clinical trials, including phase 1 and some phase 2a studies, serve as a pivotal step for biotech companies, laying the foundation for a drug candidate’s journey to market.
LINCOLN, Neb.--(BUSINESS WIRE)--Celerion, a global leader in early clinical research, proudly announces a new agreement to relocate its U.K. Phase 1 clinical research operations to iREACH Health.
Back to top Dr. Balachandran is affiliated with the David M. Rubenstein Center for Pancreatic Cancer Research. The phase 1 clinical trial was sponsored by Memorial Sloan Kettering Cancer Center. The ...
Phase Ib trial to evaluate CS5001 in combination with R-CHOP as a first-line treatment for diffuse large B-cell lymphoma (DLBCL), aiming to reshape the standard-of-care landscape. CS5001 is also being ...
The US clinical trials market is extensively segmented by different phases of clinical research, service types, indications, and geographical landscapes. The segmentation is indicative of a ...
THE US headquartered clinical research firm Celerion has announced it will relocate its Belfast operation to the new Queen’s ...
The materials explore and explain voluntary participation, phases of clinical research, and privacy and confidentiality in research. The materials will be housed in the ASH Research Collaborative ...
Regarding patients with HER2-negative, estrogen receptor (ER)-positive breast cancer, the phase 3 KEYNOTE-756 study is ...
Monroe Biomedical Research (MBR), a dedicated clinical trial site, is growing its footprint to enhance early-phase clinical trials and attract more research opportunities to North Carolina.
Madrigal Pharmaceuticals (MDGL) reported positive two-year results from the open-label compensated MASH cirrhosis arm of the Phase 3 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results